(Q37996099)

26 August 2017

Anti-obesity drugs: a review about their effects and their safety (English)

1 reference

26 August 2017

0 references

Pamela Maffioli

2

0 references

Giuseppe Derosa

object named as

Giuseppe Derosa

series ordinal

1

0 references

language of work or name

English

0 references

publication date

23 March 2012

1 reference

Expert Opinion on Drug Safety

26 August 2017

1 reference

26 August 2017

11

1 reference

26 August 2017

3

1 reference

26 August 2017

459-471

1 reference

The obesity paradox: impact of obesity on the prevalence and prognosis of cardiovascular diseases

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Rimonabant and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Methylphenidate hydrochloride increases energy expenditure in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Weight management and current options in pharmacotherapy: orlistat and sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Orlistat enhances warfarin effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Endocannabinoid control of food intake and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects on weight reduction and safety of short-term phentermine administration in Korean obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

L-carnitine--metabolic functions and meaning in humans life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Endocannabinoids and the control of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

An endocannabinoid hypothesis of drug reward and drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Pain modulation by release of the endogenous cannabinoid anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Pharmacological therapy of obesity: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Pharmacological therapies for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Roles of pancreatic polypeptide in regulation of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Pancreatic polypeptide reduces appetite and food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Oxyntomodulin : a novel potential treatment for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

21 January 2018

From obesity to diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Metabolic Control and Prevalent Cardiovascular Disease in Non-Insulin-dependent Diabetes Mellitus (NIDDM): The NIDDM Patient Outcomes Research Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.675326

Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.18433/J3388P

Identifiers

DOI

10.1517/14740338.2012.675326

1 reference

26 August 2017

1 reference

PubMed ID

22439841